Non-invasive Assessment to Understand and Manage Moderate or Severe Tricuspid Regurgitation Using Lung and Liver Imaging Technologies

What this Trial Is About

Tricuspid regurgitation TR is a heart valve condition increasingly recognized for its serious impact on health, especially in patients with heart failure with preserved ejection fraction HFpEF. This condition is linked to higher risks of hospitalization and death. The study aims to understand the complex relationship between TR, heart function, and related factors like liver stiffness and lung fluid, using non-invasive tools to better predict outcomes and improve treatments for different types of TR. Participants will be grouped based on whether they receive medical treatment or transcatheter intervention for moderate or greater TR. The study uses advanced diagnostic devices such as the ReDS Pro, which measures lung fluid through electromagnetic signals, and Fibroscan, which assesses liver stiffness with ultrasound. These assessments help characterize the heart and lung conditions without invasive procedures. During the study, participants will undergo regular evaluations including heart function tests, lung fluid and liver stiffness measurements, and quality of life assessments. Researchers will track outcomes such as rates of heart failure hospitalizations, tricuspid interventions, and cardiovascular deaths over one year. The study monitors changes in heart performance and therapy adjustments to understand how these relate to patient health and treatment decisions.

Application of Comprehensive Non-invasive Assessment To Phenotype Tricuspid Regurgitation